Clinical Trial Update: Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a three-drug regimen (Tacrolimus, Bortezomib, and Thymoglobulin) to prevent low-toxicity graft-versus-host disease in donor-derived blo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia Bcr-abl1 Positive
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Myelodysplastic Syndrome

Drugs mentioned

• Bortezomib (bortezomib)
• Tacrolimus (Tacrolimus)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Emory University | Conditions: Acute Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2018-04-30